Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy

NeuroReport

Volumn 7, Issue 12, 1996, Pages 1881-1886

  Kanbayashi, Takashi ^a   Nishino, Seiji ^a   Tafti, Mehdi ^a   Hishikawa, Yasuo ^b   Dement, William C ^a   Mignot, Emmanuel ^a  

^a STANFORD UNIVERSITY   (United States)

^b AKITA UNIVERSITY   (Japan)

Author keywords

cataplexy; cytokines; immune system; microglia; narcolepsy; thalidomide; TNF ; hydroxybutyrate

Indexed keywords

4 HYDROXYBUTYRIC ACID; DIAZEPAM; HYPNOTIC AGENT; NEUROTRANSMITTER RECEPTOR; PENTOBARBITAL; THALIDOMIDE;

ARTICLE; CATAPLEXY; CONTROLLED STUDY; DOG; IMMUNE SYSTEM; INTRAVENOUS DRUG ADMINISTRATION; NARCOLEPSY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REM SLEEP;

EID: 0029860768     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199608120-00002     Document Type: Article

References (25)

1. Guilleminault C. Narcolepsy syndrome. In: Kryger MH, Roth T and Dement WC, eds. Principles and Practice of Sleep Medicine. Philadelphia: Saunders, 1994: 549-561.
2. Hublin C, Partinen M, Kaprio J et al. Sleep 17(Suppl). S7-12 (1994).
3. Baker TL and Dement WC. Canine narcolepsy-cataplexy syndrome: evidence for an inherited monoaminergic-cholinergic imbalance. In: McGinty DJ, Drucker-Colin R, Morrison A et al, eds. Brain Mechanism of Sleep. New York: Raven Press, 1985: 199-233.
4. Mignot E, Wang C, Rattazzi C et al. Proc Natl Acad Sci USA 88, 3475-3478 (1991).
5. Nishino S, Reid MS, Dement WC et al. Sleep 17(Suppl) S84-S92 (1994).
6. Matsuki K, Grumet FC, Lin X et al. Lancet 339, 1052 (1992).
7. Mignot E, Tafti M, Dement WC et al Adv Neuroimmunol 5, 23-37 (1995).
8. Tafti M, Nishino S, Aldrich MS et al. J. Neurosci 16, 4588-4595 (1996).
9. McGeer PL, Kawamata T, Walker DG et al. Glia 7, 84-92 (1993).
10. Nakajima K and Kohsaka S. Neurosci Res 17, 187-203 (1993).
11. Gunzler V. Drug Safety 7, 116-134 (1992).
12. Kaplan G. Immunobiology 191, 564-568 (1994).
13. Sampaio EP, Kaplan G, Miranda A et al. J Infect Dis 168, 408-414 (1993).
14. Nishimura K, Hashimoto Y and Iwasaki S. Biochem Biophys Res Commun 199, 455-460 (1994).
15. Krueger JM, Takahashi S, Kapas L et al. Adv Neuroimmunol 5, 171-188 (1995).
16. Snoham S, Davenne D, Cady AB et al. Am J Physiol 253, R142-R149 (1987).
17. Nishino S, Haak L, Shepherd H et al. J Pharmacol Exp Ther 253, 1145-1152 (1990).
18. Nishino S, Tafti M, Reid MS et al. J Neurosci 15, 4806-4814 (1995).
19. Frederickson RC, Slater IH, Dusenberry WE et al. J Pharmacol Exp Ther 203, 240-251 (1977).
20. Kaitin KI. Psychopharmacology 85, 47-50 (1985)
21. Scrima L, Hartman PG, Johnson FH Jr et al. Biol Psychiatry 26, 331-343 (1989).
22. Price PA, Schachter M, Smith SJ et al. Ann Neurol 9, 198 (1981).
23. Raivich G, Moreno-Flores MT, Muller JC et al. Neuropathol Appl Neurobiol 20, 209-211 (1994).
24. Peterson PK, Hu S, Sheng WS et al. J Infect Dis 172, 1137-1140 (1995).
25. Jacob CO, Fronek Z, Lewis GD et al. Proc Natl Acad Sci USA 87, 1233-1237 (1990).